NCT06533644View on ClinicalTrials.gov

A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 29, 2025

Primary Completion Date

December 14, 2027

Study Completion Date

December 14, 2027

Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
PROCEDURE

Partial Oncolysis

Partial tumor oncolysis will be completed by cryolysis.

DRUG

SV-102

Intratumoral infusion of SV-102

Trial Locations (5)

15213

RECRUITING

University of Pittsburgh Medical Center, Pittsburgh

19096

RECRUITING

Lankenau Institute for Medical Research, Wynnewood

48084

RECRUITING

Michigan Institute of Urology, Troy

68105

NOT_YET_RECRUITING

University of Nebraska Medical Center, Omaha

85719

RECRUITING

University of Arizona Cancer Center, Tucson

All Listed Sponsors
lead

Syncromune, Inc.

INDUSTRY

NCT06533644 - A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter